Enanta Pharmaceuticals, Inc. Stock price
Equities
ENTA
US29251M1062
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.46 USD | +5.63% | +19.34% | +85.55% |
Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
Financials (USD)
Sales 2024 * | 68.81M | Sales 2025 * | 73.31M | Capitalization | 369M |
---|---|---|---|---|---|
Net income 2024 * | -110M | Net income 2025 * | -116M | EV / Sales 2024 * | 5.37 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.04 x |
P/E ratio 2024 * |
-3.35
x | P/E ratio 2025 * |
-3.54
x | Employees | 145 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.9% |
Latest transcript on Enanta Pharmaceuticals, Inc.
1 day | +5.63% | ||
1 week | +19.34% | ||
Current month | +21.50% | ||
1 month | +22.10% | ||
3 months | +78.89% | ||
6 months | +54.51% | ||
Current year | +85.55% |
Managers | Title | Age | Since |
---|---|---|---|
Jay Luly
CEO | Chief Executive Officer | 67 | 03-06-30 |
Paul Mellett
DFI | Director of Finance/CFO | 68 | 03-08-31 |
Chief Tech/Sci/R&D Officer | 50 | 22-08-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Foletta
BRD | Director/Board Member | 63 | 20-06-28 |
Lesley Russell
BRD | Director/Board Member | 63 | 16-11-17 |
Bruce Carter
CHM | Chairman | 80 | 13-11-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 17.46 | +5.63% | 304,820 |
24-03-27 | 16.53 | +3.64% | 476,790 |
24-03-26 | 15.95 | +14.42% | 477,223 |
24-03-25 | 13.94 | -4.46% | 132,434 |
24-03-22 | 14.59 | -0.27% | 392,276 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+85.55% | 350M | |
+9.30% | 45.97B | |
+52.73% | 43.93B | |
+7.15% | 42.34B | |
-8.78% | 28.27B | |
+18.68% | 27.18B | |
-21.92% | 19.44B | |
+14.62% | 13.83B | |
+31.85% | 12.4B | |
+4.47% | 11.45B |